Exclusive Summary

• **Validated Regulatory Status**: UB140 is the only Chinese PCSK9 siRNA to receive FDA IND approval to date, validating its CMC and preclinical quality for global partners.
• **Potential Best-in-Class Efficacy**: Head-to-head preclinical data demonstrates superior durability and depth of LDL-C reduction compared to Novartis' Inclisiran, along with significant Lp(a) lowering capabilities.
• **Clean Intellectual Property**: Features a proprietary GalNAc delivery platform with Freedom-to-Operate (FTO) confirmed, avoiding patent overlaps with major competitors like Alnylam/Novartis.
• **Superior Patient Compliance**: Offers an ultra-long-acting profile with twice-yearly dosing (Q6M), addressing the critical unmet need for adherence in chronic lipid management.

Asset Materials

Contact Us for Full Materials